title: Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma.
abstract: Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.
authors.affiliation: a Medical Oncology , Azienda Ospedaliera Universitaria Integrata, University of Verona , Verona , Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Massari
authors.affiliation: a Medical Oncology , Azienda Ospedaliera Universitaria Integrata, University of Verona , Verona , Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Ciccarese
authors.affiliation: b Clinica di Oncologia Medica, AOU Ospedali Riuniti , Polytechnic University of Marche , Ancona , Italy.
authors.forename: Matteo
authors.initials: M
authors.lastname: Santoni
authors.affiliation: c Department of Surgery , Cordoba University Medical School , Cordoba , Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Lopez-Beltran
authors.affiliation: d Section of Pathological Anatomy , Polytechnic University of the Marche Region , Ancona , Italy.
authors.forename: Marina
authors.initials: M
authors.lastname: Scarpelli
authors.affiliation: d Section of Pathological Anatomy , Polytechnic University of the Marche Region , Ancona , Italy.
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Montironi
authors.affiliation: e Department of Pathology and Laboratory Medicine , Indiana University School of Medicine , Indianapolis , IN , USA.|f Department of Urology , Indiana University School of Medicine , Indianapolis , IN , USA.
authors.forename: Liang
authors.initials: L
authors.lastname: Cheng
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000098:blood supply* / Q000188:drug therapy / Q000473:pathology; D015195:Drug Design; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D058990:Molecular Targeted Therapy; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism*
chemical_list: D020533:Angiogenesis Inhibitors; D017468:Receptors, Fibroblast Growth Factor
keywords: fibroblast growth factor receptor; kidney; personalized medicine; precision medicine; renal cell carcinoma; targeted therapy; vascular endothelial growth factor receptor